ALB and metastatic prostate carcinoma: Wang et al. investigated the pretreatment serum albumin/globulin ratio as being an independent prognostic biomarker for progression free survival and cancer specific survival in patients with metastatic prostate cancer who had been receiving maximal androgen blockade treatment (Wang et al., 2018).